Commentary|Videos|November 11, 2024
A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer
Author(s)Haley M. Hill, PA-C
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
4
Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer
5